Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus HYDROCHLOROTHIAZIDE VALSARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus HYDROCHLOROTHIAZIDE VALSARTAN.
BENICAR HCT vs HYDROCHLOROTHIAZIDE; VALSARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Oral, 12.5-25 mg hydrochlorothiazide / 80-320 mg valsartan once daily. Maximum dose: 25 mg hydrochlorothiazide / 320 mg valsartan per day.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Hydrochlorothiazide: 6-15 hours (terminal); clinical effect persists due to tubular secretion. Valsartan: 6 hours (terminal); no accumulation with once-daily dosing.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Hydrochlorothiazide: ~70% renal (unchanged) via tubular secretion; ~30% biliary/fecal. Valsartan: 83% fecal (unchanged); 13% renal (unchanged and metabolites).
Category C
Category D/X
ARB + Thiazide Diuretic
ARB